M. Krause

发表

Inhibitors in PTP'S: A Retrospective Study in Germany

J. Oldenburg, W. Miesbach, C. Auer, 2006 .

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998, The New England journal of medicine.

Hemostatic and hemorrhagic problems in neurosurgical patients

V. Seifert, M. Krause, Klaus Görlinger, 2009, Acta Neurochirurgica.

CD36‐fibrin interaction propagates FXI‐dependent thrombin generation of human platelets

U. Walter, K. Jurk, J. Lutz, 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

High-throughput elucidation of thrombus formation reveals sources of platelet function variability

W. Ouwehand, K. Downes, S. Sivapalaratnam, 2018, Haematologica.

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A

W. Kreuz, M. Krause, I. Scharrer, 2006, Platelets.

Thrombophilic Risk Parameters in Juvenile »Idiopathic« Stroke Patients

S. Ehrenforth, M. Krause, I. Scharrer, 2002 .

U. Nowak‐Göttl, M. Krause, A. Kruempel, 2017, Blood cells, molecules & diseases.

Diagnose angeborener Störungen der Thrombozytenfunktion

O. Meyer, T. Scholl, C. Geisen, 2014, Hämostaseologie.

The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia.

S. Ehrenforth, M. Krause, I. Scharrer, 1998, Blood.

Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial

J. Goudemand, W. Schramm, G. Kenet, 2009, Thrombosis and Haemostasis.

Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency

E. Seifried, J. Oldenburg, D. Delev, 2018 .

The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

W. Miesbach, C. Auer, M. Krause, 2005, British journal of haematology.

Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland

L. Alberio, J. Oldenburg, P. Knöbl, 2009, Annals of Hematology.

Inquiry into the Significance of Constantly Raised FVIII Values as a Factor in Thrombophilia

C. Rabenstein, M. Krause, I. Scharrer, 2002 .

Five Novel Mutations in F13B Gene Resulting in Mild FXIII Deficiency

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007 .

Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Therapie hereditärer Thrombozytopathien

R. Zotz, U. Scholz, W. Kreuz, 2014, Hämostaseologie.

[Therapy of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e. V.)].

R. Zotz, U. Scholz, W. Kreuz, 2014, Hamostaseologie.

Antidotal Effects of Non-Specific Reversal Agents On Anticoagulant-Induced Inhibition of Thrombin Generation.

M. Krause, T. Scholz, R. Schwerdtfeger, 2012 .

Vaccination in patients with haemophilia—Results from an online survey among haemophilia treatment centres in Germany

C. Königs, M. Krause, J. Wendisch, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Is there a Correlation between vWF-cleaving Protease-Activity, vWF:Ag, Clinical Course and Number of Relapses in 15 Patients with TTP?

M. Krause, I. Scharrer, M. Böhm, 2003 .

Von-Willebrand Factor Cleaving Protease (ADAMTS-13) Activity in Various Thrombotic, Hemolytic and Autoimmune Disorders

W. Miesbach, M. Krause, I. Scharrer, 2004 .

Immunoadsorption with single‐use columns for the management of bleeding in acquired hemophilia A: A series of nine cases

M. Krause, H. Geiger, C. Betz, 2007, Journal of clinical apheresis.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

C. Königs, J. Healey, P. Lollar, 2017, Blood.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.

R. Greil, P. Neumeister, A. Koch, 2015, Blood.

Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia

C. Königs, J. Oldenburg, R. Klamroth, 2021, Hämostaseologie.

Major Orthopedic Reconstructions in an Inhibitor Patient — A Case Report

W. Miesbach, M. Krause, I. Scharrer, 2005 .

Evaluation of Thrombotic Events in Hemophiliacs Undergoing Major Orthopedic Surgery Without Thrombosis Prophylaxis

C. Auer, M. Krause, I. Scharrer, 2005 .

Cardiovascular interventions in patients with haemophilia and severe von Willebrand disease

U. Scholz, R. Klamroth, K. Holstein, 2008, Hämostaseologie.

Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

T. Wienker, A. Hoerauf, J. Oldenburg, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients

M. Krause, I. Scharrer, A. Hahn, 2006 .

Identification of Inhibitor Epitopes in Acquired Hemophilia by Phage Display

C. Königs, W. Kreuz, M. Krause, 2007 .

Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency

E. Seifried, J. Oldenburg, D. Delev, 2012 .

Relevance of a single dose of 270 μg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors

J. Oldenburg, G. Auerswald, R. Zotz, 2009, Hämostaseologie.

Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage

A. von Eckardstein, A. Heinecke, R. Klamroth, 2005, Thrombosis and Haemostasis.

Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.

R. Junker, G. Kenet, U. Nowak‐Göttl, 2016, Thrombosis research.

Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency

E. Seifried, C. Geisen, A. Pavlova, 2013, Thrombosis and Haemostasis.

A family with an interesting variant of Glanzmann‘s thrombasthenia

M. Krause, R. Mahnel, T. Scholz, 2009, Hämostaseologie.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998 .

Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII

C. Auer, M. Krause, I. Scharrer, 2006 .

Molecular basis of antithrombin deficiency.

E. Seifried, J. Oldenburg, D. Delev, 2011, Thrombosis and haemostasis.

Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.

R. Junker, G. Kenet, M. Krause, 2016, Thrombosis research.

The Role of VWF:Ag II in Patients with Acquired von Willebrand Disease

M. Krause, I. Scharrer, C. Caron, 2005 .